LIGAND PHARMACEUTICALS INCORPORATED
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $821.2M | $19.5M |
| FY2022 | — | $597.5M | $45.0M |
| FY2023 | — | $700.9M | $23.0M |
| FY2024 | — | $830.4M | $72.3M |
| FY2025 | — | $1.02B | $174.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $821.2M | $19.5M |
| FY2022 | — | $597.5M | $45.0M |
| FY2023 | — | $700.9M | $23.0M |
| FY2024 | — | $830.4M | $72.3M |
| FY2025 | — | $1.02B | $174.9M |